Application of GnRH antagonist in combination with clomiphene citrate and hMG for patients with exaggerated ovarian response in previous IVF/ICSI cycles

Journal of Assisted Reproduction and Genetics

Volumn 24, Issue 8, 2007, Pages 331-336

  Lin, Yu Hung ^a,b,c   Seow, Kok Min ^a   Hsieh, Bih Chwen ^a,b   Huang, Lee Wen ^a,b   Chen, Heng Ju ^a   Huang, Shih Chia ^a   Chen, Chih Yu ^a   Chen, Pei Hsin ^a   Hwang, Jiann Loung ^a,b,d   Tzeng, Chi Ruey ^d  

^a SHIN KONG WU HO SU MEMORIAL HOSPITAL   (Taiwan)

^b FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^c NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^d TAIPEI MEDICAL UNIVERSITY   (Taiwan)

Author keywords

Cetrorelix; Coasting; GnRH agonist; GnRH antagonist; Ovarian hyperstimulation syndrome

Indexed keywords

BUSERELIN ACETATE; CETRORELIX; CHORIONIC GONADOTROPIN; CLOMIFENE CITRATE; HUMAN MENOPAUSAL GONADOTROPIN; PREGONAL; PROGESTERONE; UNCLASSIFIED DRUG;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG DOSE REDUCTION; ESTRADIOL BLOOD LEVEL; FEMALE; FERTILIZATION IN VITRO; HUMAN; INCIDENCE; INFERTILITY; INTRACYTOPLASMIC SPERM INJECTION; OVARY HYPERSTIMULATION; PRIORITY JOURNAL; TREATMENT RESPONSE; UNSPECIFIED SIDE EFFECT;

ADULT; CLOMIPHENE; DRUG THERAPY, COMBINATION; EMBRYO TRANSFER; ESTRADIOL; FEMALE; FERTILITY AGENTS, FEMALE; FERTILIZATION IN VITRO; FOLLICLE STIMULATING HORMONE; GONADOTROPIN-RELEASING HORMONE; HORMONE ANTAGONISTS; HUMANS; MENOTROPINS; OVARIAN HYPERSTIMULATION SYNDROME; OVULATION INDUCTION; PREGNANCY; PREGNANCY RATE; PROSPECTIVE STUDIES; SPERM INJECTIONS, INTRACYTOPLASMIC; SUPEROVULATION; TREATMENT OUTCOME;

EID: 34548422779     PISSN: 10580468     EISSN: None     Source Type: Journal    
DOI: 10.1007/s10815-007-9127-8     Document Type: Article

References (30)

1. Brinsden PR, Wada I, Tan SL, Balen A, Jacobs HS. Diagnosis, prevention and management of ovarian hyperstimulation syndrome. Br J Obstet Gynaecol 1995;102:767-72.
2. Whelan JG, Vlahos NF. The ovarian hyperstimulation syndrome. Fertil Steril 2000;73:883-96.
3. Delvigne A, Rozenberg S. Epidemiology and prevention of ovarian hyperstimulation syndrome (OHSS): a review. Hum Reprod Update 2002;8:559-77.
4. Chen D, Burmeister L, Goldschlag D, Rosenwaks Z. Ovarian hyperstimulation syndrome: strategies for prevention. Reprod Biomed Online 2003;7:43-9.
5. Delvigne A, Rozenberg S. Preventive attitude of physicians to avoid OHSS in IVF patients. Hum Reprod 2001;16:2491-5.
6. Levinsohn-Tavor O, Friedler S, Schachter M, Raziel A, Strassburger D, Ron-El R. Coasting-what is the best formula? Hum Reprod 2003;18:937-40.
7. Ulug U, Bahceci M, Erden HF, Shalev E, Ben-Shlomo I. The significance of coasting duration during ovarian stimulation for conception in assisted fertilization cycles. Hum Reprod 2002;17:310-3.
8. Mansour R, Aboulghar M, Serour G, Amin Y, Abou-Setta AM. Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome. Hum Reprod 2005;20:3167-72.
9. Biljan MM, Tan SL. GnRH agonists in gonadotrophin ovulation induction: characteristics of long regimens. In: Filicori M, Flamigani C, editors. Ovulation induction: update 98. New York: Parthenon; 1998. p. 75-82.
10. Hwang JL, Huang LW, Hsieh BC, Tsai YL, Huang SC, Chen CY, et al. Ovarian stimulation by clomiphene citrate and hMG in combination with cetrorelix acetate for ICSI cycles. Hum Reprod 2003;18:45-9.
11. MacDougall MJ, Tan SL, Jacobs HS. In-vitro fertilization and the ovarian hyperstimulation syndrome. Hum Reprod 1992;7:597-600.
12. Olivennes F, Belaisch-Allart J, Emperaire JC, Dechaud H, Alvarez S, Moreau L, et al. Prospective, randomized, controlled study of in vitro fertilization-embryo transfer with a single dose of a luteinizing hormone-releasing hormone (LH-RH) antagonist (cetrorelix) or a depot formula of an LH-RH agonist (triptorelin). Fertil Steril 2000;73:314-20.
13. Chen CD, Wu MY, Chao KH, Chen SU, Ho HN, Yang YS. Serum estradiol level and oocyte number in predicting severe ovarian hyperstimulation syndrome. J Formos Med Assoc 1997;96:829-34.
14. Benadiva CA, Davis O, Kligman I, Moomjy M, Liu HC, Rosenwaks Z. Withholding gonadotrophin administration is an effective alternative for the prevention of ovarian hyperstimulation syndrome. Fertil Steril 1997;67:724-7.
15. Golan A, Ron-el R, Herman A, Soffer Y, Weinraub Z, Caspi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol Surv 1989;44:430-40.
16. Tortoriello DV, McGovern PG, Colon JM, Skurnick JH, Lipetz K, Santoro N. "Coasting" does not adversely affect cycle outcome in a subset of highly responsive in vitro fertilization patients. Fertil Steril 1998;69:454-60.
17. Waldenstrom U, Kahn J, Marsk L, Nilsson S. High pregnancy rates and successful prevention of severe ovarian hyperstimulation syndrome by 'prolonged coasting' of very hyperstimulated patients: a multicentre study. Hum Reprod 1999;14:294-7.
18. Isaza V, Garcia-Velasco JA, Aragones M, Remohi J, Simon C, Pellicer A. Oocyte and embryo quality after coasting: the experience from oocyte donation. Hum Reprod 2002;17:1777-82.
19. Moreno L, Diaz I, Pacheco A, Zuniga A, Requene A, Garcia-Velasco JA. Extended coasting duration exerts a negative impact on IVF cycle outcome due to premature luteinization. Reprod Biomed Online 2004;9:500-4.
20. Ulug U, Ben-Shlomo I, Bahceci M. Predictors of success during the coasting period in high-responder patients undergoing controlled ovarian stimulation for assisted conception. Fertil Steril 2004;82:338-42.
21. Egbase PE, Sharhan MA, Grudzinskas JG. Early unilateral follicular aspiration compared with coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study. Hum Reprod 1999;14:1421-5.
22. Delvigne A, Kostyla K, Murillo D, Van Hoeck J, Rozenberg S. Oocyte quality and IVF outcome after coasting to prevent ovarian hyperstimulation syndrome. Int J Fertil Womens Med 2003;48:25-31.
23. Dhont M, Van der Streten F, De Sutter P. Prevention of severe ovarian hyperstimulation by coasting. Fertil Steril 1998;70:847-50.
24. Lee C, Tummon I, Martin J, Nisker J, Power S, Tekpetey F. Does withholding gonadotrophin administration prevent severe ovarian hyperstimulation? Hum Reprod 1998;13:1157-8.
25. Valbuena D, Jasper M, Remohi J, Pellicer A, Simon C. Ovarian stimulation and endometrial receptivity. Hum Reprod 1999;14 Suppl 2:107-11.
26. Marci R, Senn A, Dessole S, Chanson A, Loumaye E, De Grandi P, et al. A low-dose stimulation protocol using highly purified follicle-stimulating hormone can lead to high pregnancy rates in in vitro fertilization patients with polycystic ovaries who are at risk of a high ovarian response to gonadotrophins. Fertil Steril 2001;75:1131-5.
27. Damario MA, Barmat L, Liu HC, Davis OK, Rosenwaks Z. Dual suppression with oral contraceptives and gonadotrophin releasing-hormone agonists improves in-vitro fertilization outcome in high responder patients. Hum Reprod 1997;12:2359-65.
28. Fiedler K, Ludwig M. Use of clomiphene citrate in in vitro fertilization (IVF) and IVF/intracytoplasmic sperm injection cycles. Fertil Steril 2003;80:1521-3.
29. Engel JB, Ludwig M, Felberbaum R, Albano C, Devroey P, Diedrich K. Use of cetrorelix in combination with clomiphene citrate and gonadotrophins: a suitable approach to 'friendly IVF'? Hum Reprod 2002;17:2022-6.
30. Tavaniotou A, Albano C, Van Steirteghem A, Devroey P. The impact of LH serum concentration on the clinical outcome of IVF cycles in patients receiving two regimens of clomiphene citrate/gonadotrophin/0.25 mg cetrorelix. Reprod Biomed Online 2003;6:421-6.